Table 4.
HRs of Incident ASCVD, IHD, and Cerebral Infarction Related to Elevated Baseline Circulating FGF21 Levels of >232.0 pg/mL
| Cases, No. (%) | Unadjusted | Fully Adjusted Model | |||
|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | ||
| Whole cohort (N=705) | |||||
| Total ASCVD | 80 (11.3) | 2.984 (1.607–5.540) | 0.001 | 2.176 (1.156–4.096) | 0.016 |
| IHD | 36 (5.10) | 5.691 (1.736–18.654) | 0.004 | 3.904 (1.153–13.213) | 0.029 |
| Cerebral infarction | 44 (6.2) | 2.276 (1.057–4.900) | 0.036 | 1.918 (0.862–4.266) | 0.11 |
| Patients without DM at baseline (n=602) | |||||
| Total ASCVD | 55 (9.1) | 4.602 (1.958–10.813) | <0.001 | 3.185 (1.319–7.693) | 0.01 |
| IHD | 27 (4.5) | 6.497 (1.534–27.515) | 0.011 | 4.536 (1.013–20.307) | 0.048 |
| Cerebral infarction | 28 (4.7) | 4.523 (1.364–15.000) | 0.014 | 4.188 (1.193–14.704) | 0.025 |
| Patients with DM at baseline (n=103) | |||||
| Total ASCVD | 25 (24.3) | 1.098 (0.430–2.803) | 0.845 | 1.398 0.478–4.086) | 0.541 |
| IHD | 9 (8.7) | 3.622 (0.423–31.018) | 0.24 | 14.317 (0.281–730.75) | 0.185 |
| Cerebral infarction | 16 (15.5) | 0.691 (0.240–1.990) | 0.494 | 0.696 (0.186–2.603) | 0.59 |
Fully adjusted model: adjusted for age, sex, body mass index, fasting blood glucose, glycated hemoglobin, homeostatic model assessment for insulin resistance index, estimated glomerular filtration rate, high‐sensitivity C‐reactive protein, lipocalin‐2, smoking status (never, ever‐smoker), dyslipidemia (yes/no), and hypertension (yes/no). ASCVD indicates atherosclerotic cardiovascular disease; DM, diabetes mellitus; FGF21, fibroblast growth factor 21; HR, hazard ratio; and IHD, ischemic heart disease.